Grifols, S.A. (GRFS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Grifols, S.A. (GRFS) Healthcare & Pipeline Overview

Grifols, S.A., a global healthcare leader based in Barcelona, focuses on plasma-derived therapies and diagnostic solutions. With a diverse portfolio spanning bioscience, hospital, diagnostic, and bio supplies, Grifols serves a wide range of healthcare needs, addressing chronic, rare, and life-threatening conditions, and operates with a P/E ratio of 14.63.

What Is the Investment Thesis for GRFS?

The company's diverse product portfolio, spanning bioscience, hospital, diagnostic, and bio supplies, provides multiple revenue streams and reduces reliance on any single product. With a current profit margin of 5.3% and a gross margin of 38.4%, Grifols demonstrates solid profitability. Key growth catalysts include increasing demand for plasma-derived therapies, expansion into emerging markets, and continued innovation in diagnostic solutions. However, potential risks include regulatory changes, competition from other players like Baxter International (BAX), and fluctuations in plasma supply. The company's commitment to research and development, coupled with its global presence, positions it for sustained growth in the healthcare sector.

Based on FMP financials and quantitative analysis

GRFS Key Highlights

Market capitalization of $6.59B reflects Grifols' significant presence in the healthcare sector.

• P/E ratio of 14.63 indicates a potentially undervalued stock relative to its earnings.
• Gross margin of 38.4% demonstrates the company's ability to maintain profitability in its operations.
• Dividend yield of 1.63% provides a steady income stream for investors.
• Beta of 1.19 suggests a slightly higher volatility compared to the overall market.

Who Are GRFS's Competitors?

GRFS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GRFS's Key Strengths?

Leading position in plasma-derived therapies.

• Diverse product portfolio.
• Global presence and distribution network.
• Strong relationships with healthcare providers.

What Are GRFS's Weaknesses?

Reliance on plasma supply.

• Exposure to regulatory changes.
• High debt levels.
• Competition from other major players.

What Could Drive GRFS Stock Higher?

GRFS catalyst: Increasing demand for plasma-derived therapies due to the rising prevalence of chronic and rare diseases.

• Expansion into emerging markets, providing new revenue streams and growth opportunities.
• Potential regulatory approvals for new diagnostic solutions and therapies.
• Strategic acquisitions to expand product portfolio and technological capabilities.

What Are the Key Risks for GRFS?

Financial-distress signal — its Altman Z-Score of 1.06 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Fluctuations in plasma supply, impacting production and profitability.
• Pricing pressures from competitors and healthcare providers.
• Regulatory changes affecting the approval and marketing of plasma-derived therapies.
• Economic downturns impacting healthcare spending and demand for products.

What Are the Growth Opportunities for GRFS?

• Expansion in Emerging Markets: Grifols has the opportunity to expand its presence in emerging markets, where demand for plasma-derived therapies is growing rapidly. By establishing strategic partnerships and distribution networks in these regions, Grifols can tap into new revenue streams and diversify its geographic footprint. The emerging markets for plasma-derived products are projected to reach $15 billion by 2030.
• New Product Development: Continued investment in research and development will enable Grifols to develop innovative diagnostic solutions and therapies that address unmet medical needs. By focusing on areas such as Alzheimer's disease and cancer diagnostics, Grifols can create new revenue streams and enhance its competitive advantage. The market for novel diagnostic solutions is expected to reach $80 billion by 2028.
• Strategic Acquisitions: Grifols can pursue strategic acquisitions to expand its product portfolio, enhance its technological capabilities, and gain access to new markets. By acquiring companies with complementary technologies or product lines, Grifols can strengthen its position in the healthcare industry and accelerate its growth. The global M&A market in the healthcare sector is estimated at $400 billion annually.
• Plasma Collection Network Expansion: Expanding its plasma collection network will ensure a stable and cost-effective supply of plasma, which is essential for the production of its plasma-derived therapies. By opening new plasma donation centers and implementing innovative plasma collection technologies, Grifols can reduce its reliance on third-party suppliers and improve its profitability. The global plasma collection market is valued at $25 billion.
• Technological Advancements in Manufacturing: Implementing advanced manufacturing technologies, such as automation and artificial intelligence, can improve the efficiency and reduce the costs of its production processes. By investing in these technologies, Grifols can enhance its competitiveness and increase its profitability. The market for automation in the pharmaceutical industry is projected to reach $15 billion by 2027.

What Are GRFS's Competitive Advantages?

• Proprietary plasma fractionation technology.
• Extensive plasma collection network.
• Strong relationships with healthcare providers.
• Global presence and distribution network.

What Does GRFS Do?

Founded in 1940 in Barcelona, Spain, Grifols, S.A. has evolved into a global healthcare company specializing in plasma-derived medicines and other innovative solutions. The company operates through four primary divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies. The Bioscience division, the company's core, focuses on researching, developing, producing, and marketing plasma-derived medicines to treat patients with chronic, rare, prevalent, and life-threatening diseases. Its key products include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies, including clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products used across the healthcare continuum, from prevention and screening to diagnosis, prognosis, and treatment monitoring. The Bio Supplies division provides biological materials for life-science research, clinical trials, and pharmaceutical and diagnostic product manufacturing. Grifols serves a global customer base, including public and private healthcare providers, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care institutions, and national health systems. The company has a technology collaboration agreement with Mondragon, enhancing its innovation capabilities. Grifols' commitment to advancing healthcare through plasma-derived therapies and diagnostic solutions has solidified its position as a key player in the global healthcare market.

What Products and Services Does GRFS Offer?

• Develops and manufactures plasma-derived therapies.
• Offers diagnostic solutions for disease prevention, screening, and monitoring.
• Provides hospital products and medical supplies.
• Supplies biological materials for life-science research and clinical trials.
• Treats patients with hemophilia, immune deficiencies, and infectious diseases.
• Serves public and private healthcare providers globally.

How Does GRFS Make Money?

• Generates revenue through the sale of plasma-derived therapies.
• Earns income from diagnostic products and services.
• Sells hospital products and medical supplies to healthcare institutions.
• Provides biological materials to research and manufacturing organizations.

What Industry Does GRFS Operate In?

Grifols operates within the global drug manufacturers industry, which is characterized by increasing demand for specialized therapies and diagnostic solutions. The market for plasma-derived therapies is expected to grow due to the rising prevalence of chronic and rare diseases, as well as advancements in diagnostic technologies. Grifols competes with other major players in the industry, including Baxter International (BAX), CSL Behring, and Takeda Pharmaceutical. The industry is subject to stringent regulatory requirements and faces challenges related to plasma supply and pricing pressures. Grifols' focus on innovation and global expansion positions it to capitalize on the growth opportunities in this dynamic market.

Who Are GRFS's Key Customers?

• Public and private healthcare providers.
• Wholesalers and distributors.
• Group purchasing organizations.
• Blood banks, hospitals, and care institutions.
• National health systems.

Company Profile

Grifols, S.A. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Barcelona, ES. The company is led by CEO Jose Ignacio Abia Buenache. GRFS has traded publicly since 2011.

Grifols, S.A. Financial Trajectory

Grifols, S.A. (GRFS) reported $2.17B in revenue for Q2 FY2026, reflecting 8.5% growth compared to the prior quarter. The company recorded net income of $178.4M, with diluted EPS of $0.27. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, GRFS averaged $0.19 in diluted EPS.

How Grifols, S.A. Is Valued

Grifols, S.A. carries a market capitalization of $6.59B, placing it in the mid-cap category. Relative to its peer group, GRFS's quantitative score of 66/100 is roughly in line with the peer average of 59/100.

Return on equity for Grifols, S.A. stands at 7.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.1%, showing how much profit it generates from its asset base. GRFS trades at a trailing price-to-earnings ratio of 14.63, below the Healthcare sector average of ~21.60x. Its free cash flow yield is 12.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.8%, the inverse of the P/E and a quick read on earnings relative to price.

Grifols, S.A.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.06 places it in the distress zone, a signal of elevated financial risk.

Grifols, S.A. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 8.1% below estimates on average.

GRFS Financials

GRFS Latest News

GRFS Analyst Consensus

GRFS MoonshotScore

GRFS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources